Does protracted antiviral therapy impact on HCV-related liver cirrhosis progression?(312 views) Tarantino G, Gentile A, Capone D, Basile V, Tarantino M, Di Minno MN, Cuocolo A, Conca P
Department of Clinical and Expermtal Medicine, Federico II University Medical School of Naples,Via S. Pansini, 5, Naples 80131, Italy. tarantin@unina.it
Department of Biomorphological and Functional Sciences, Pharmacology Section of Neuroscience Department, Federico II University Medical School of Naples, Naples 80131, Italy
References: Alter, M.J., Epidemiology of hepatitis C in the West (1995) Semin Liver Dis, 15, pp. 5-1
Poynard, T., Bedossa, P., Opolon, P., Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups (1997) Lancet, 349, pp. 825-832
Fattovich, G., Giustina, G., Degos, F., Tremolada, F., Diodati, G., Almasio, P., Nevens, F., Realdi, G., Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients (1997) Gastroenterology, 112, pp. 463-472
Niederau, C., Lange, S., Heintges, T., Erhardt, A., Buschkamp, M., Hurter, D., Nawrocki, M., Haussinger, D., Prognosis of chronic hepatitis C: Results of a large, prospective cohort study (1998) Hepatology, 28, pp. 1687-1695
Sangiovanni, A., Prati, G.M., Fasani, P., Ronchi, C., Romeo, R., Manini, M., Del Ninno, E., Colombo, M., The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients (2006) Hepatology, 43, pp. 1303-1310
Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M., Reindollar, R., Goodman, Z.D., Albrecht, J.K., Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial (2001) Lancet, 358, pp. 958-965
Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinas, G., Goncales Jr, F.L., Haussinger, D., Yu, J., Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection (2002) N Engl J Med, 347, pp. 975-982
Salomon, J.A., Weinstein, M.C., Hammitt, J.K., Goldie, S.J., Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population (2003) JAMA, 290, pp. 228-237
Valla, D.C., Chevallier, M., Marcellin, P., Payen, J.L., Trepo, C., Fonck, M., Bourliere, M., Opolon, P., Treatment of hepatitis C virus-related cirrhosis: A randomized, controlled trial of interferon alfa-2b versus no treatment (1999) Hepatology, 29, pp. 1870-1875
Shepherd, J., Brodin, H.F., Cave, C.B., Waugh, N.R., Price, A., Gabbay, J., Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: A systematic review and economic evaluation (2005) Int J Technol Assess Health Care, 21, pp. 47-54
Iacobellis, A., Siciliano, M., Perri, F., Annicchiarico, B.E., Leandro, G., Caruso, N., Accadia, L., Andriulli, A., Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: A controlled study (2007) J Hepatol, 46, pp. 206-212
Tarantino, G., Conca, P., Capone, D., Gentile, A., Polichetti, G., Basile, V., Reliability of total overnight salivary caffeine assessment (TOSCA) for liver function evaluation in compensated cirrhotic patients (2006) Eur J Clin Pharmacol, 62, pp. 605-612
Bolognesi, M., Sacerdoti, D., Merkel, C., Gerunda, G., Maffei-Faccioli, A., Angeli, P., Jemmolo, R.M., Gatta, A., Splenic Doppler impedance indices: Influence of different portal hemodynamic conditions (1996) Hepatology, 23, pp. 1035-1040
Giannini, E., Fasoli, A., Botta, F., Testa, E., Romagnoli, P., Ceppa, P., Testa, R., Long-term follow up of chronic hepatitis C patients after alpha-interferon treatment: A functional study (2001) J Gastroenterol Hepatol, 16, pp. 399-405
Schulze-Krebs, A., Preimel, D., Popov, Y., Bartenschlager, R., Lohmann, V., Pinzani, M., Schuppan, D., Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells (2005) Gastroenterology, 129, pp. 246-258
Novo, E., Marra, F., Zamara, E., Valfre di Bonzo, L., Caligiuri, A., Cannito, S., Antonaci, C., Parola, M., Dose dependent and divergent effects of superoxide anion on cell death, proliferation, and migration of activated human hepatic stellate cells (2006) Gut, 55, pp. 90-97
Nieto, N., Dominguez-Rosales, J.A., Fontana, L., Salazar, A., Armendariz-Borunda, J., Greenwel, P., Rojkind, M., Rat hepatic stellate cells contribute to the acute-phase response with increased expression of alpha1 (I) and alpha1 (IV) collagens, tissue inhibitor of metalloproteinase-1, and matrix-metalloproteinase-2 messenger RNAs (2001) Hepatology, 33, pp. 597-607
Gramenzi, A., Andreone, P., Fiorino, S., Camma, C., Giunta, M., Magalotti, D., Cursaro, C., Bernardi, M., Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis (2001) Gut, 48, pp. 843-848
O'Donohue, J., Ng, C., Catnach, S., Farrant, P., Williams, R., Diagnostic value of Doppler assessment of the hepatic and portal vessels and ultrasound of the spleen in liver disease (2004) Eur J Gastroenterol Hepatol, 16, pp. 147-155
Bayerdorffer, E., Lamerz, R., Fliege, R., Kopcke, W., Marines, G.A., Predictive value of serum procollagen-III-peptide for the survival of patients with cirrhosis (1991) J Hepatol, 13, pp. 298-304
Does protracted antiviral therapy impact on HCV-related liver cirrhosis progression?
AIM: To study the outcomes of patients with compensated hepatitis C virus-related cirrhosis.; METHODS: Twenty-four grade A5 and 11 grade A6 of Child-Pugh classification cirrhotic patients with active virus replication, treated for a mean period of 31.3 +/- 5.1 mo with moderate doses of interferon-alpha and ribavirin, were compared to a cohort of 36 patients with similar characteristics, without antiviral treatment. Salivary caffeine concentration, a liver test of microsomal function, was determined at the starting and thrice in course of therapy after a mean period of 11 +/- 1.6 mo, meanwhile the resistive index of splenic artery at ultra sound Doppler, an indirect index of portal hypertension, was only measured at the beginning and the end of study.; RESULTS: Eight out of the 24 A5- (33.3%) and 5 out of the 11 A6- (45.45%) treated-cirrhotic patients showed a significant improvement in the total overnight salivary caffeine assessment. A reduction up to 20% of the resistive index of splenic artery was obtained in 3 out of the 8 A5- (37.5%) and in 2 out of the 5 A6- (40%) cirrhotic patients with an improved liver function, which showed a clear tendency to decrease at the end of therapy. The hepatitis C virus clearance was achieved in 3 out of the 24 (12.5%) A5- and 1 out of the 11 (0.091%) A6-patients after a median period of 8.5 mo combined therapy. In the cohort of non-treated cirrhotic patients, not only the considered parameters remained unchanged, but 3 patients (8.3%) had a worsening of the Child-Pugh score (P = 0.001).; CONCLUSION: A prolonged antiviral therapy with moderate dosages of interferon-alpha and ribavirin shows a trend to stable liver function or to ameliorate the residual liver function, the entity of portal hypertension and the compensation status at acceptable costs.
Does protracted antiviral therapy impact on HCV-related liver cirrhosis progression?
No results.
Does protracted antiviral therapy impact on HCV-related liver cirrhosis progression?